Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

NCT ID: NCT02908308

Last Updated: 2023-04-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-18

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ILCOR guidelines recommend Target Temperature Management (TTM) to between 32°C and 36°C after out-of-hospital cardiac arrest, based on low quality evidence. In a previous trial, TTM at 33°C did not confer a survival benefit or improved neurological function, compared to TTM at 36°C. A lower target temperature might be beneficial compared with normothermia and early treatment of fever. Therefore the primary purpose of the TTM2-trial will be to study any differences in mortality, neurological function and quality of life between a target temperature of 33°C and standard care avoiding fever.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The TTM2 trial is a continuation of the collaboration that resulted in the previous Targeted Temperature Management after out-of-hospital cardiac arrest trial (hereafter: TTM1). With its planned size with it will supersede the TTM1 trial as the largest trial on temperature management as a post-cardiac arrest treatment.

The TTM1 trial (NCT01020916) was a multicenter, multinational, outcome assessor-blinded, parallel group, randomised clinical trial comparing two strict target temperature regimens of 33°C and 36°C in adult patients, who have sustained return of spontaneous circulation and are unconscious after out-of-hospital cardiac arrest, when admitted to hospital. The trial did not demonstrate any difference in survival until end of trial (Hazard Ratio with a point estimate in favour of 36°C of 1.06 (95% confidence interval 0.89-1.28; P=0.51) or neurologic function at six months after the arrest, measured with CPC and mRS.

The planned study is a international, multicenter, parallel group, non-commerical, randomized, superiority trial in which a target temperature om 33°C after cardiac arrest will be compared to normothermia and early treatment of fever.

Patients eligible for inclusion will be unconscious adult patients with OHCA of a presumed cardiac cause with stable return of spontaneous circulation. Randomization will be performed by a physician in the emergency department, in the angiography suite or in the intensive care unit via web-based application using permuted blocks with varying sizes, stratified by site. Due to the nature of the intervention, health care staff will not be blinded to the intervention. However, the physicians who will assess outcomes will be blinded to temperature allocation, as will those who perform prognostication.

The intervention period will commence at the time of randomization. Cooling in the hypothermia group will achieved by means of cold fluids and state-of-the-art cooling devices (intravascular or body-surface applied closed loop systems). The initial aim will be to achieve a body temperature of 33.0°C. When this has been achieved, the target temperature will be 33°C until 28 hours after randomisation. When 28 hours have passed, gradual rewarming at a rate of 1/3°C per hour will commence, this will allow 12 hours for rewarming.

In the normothermia arm the aim will be to avoid a temperature greater than or equal to 37.8°C using conservative measures. If a single temperature of 37.8° or greater is measured, active cooling with a device should be initiated and maintained until 40 hours after randomization.

All participants will be sedated, mechanically ventilated and hemodynamically supported throughout the intervention period of 40 hours. Participants in both arms who remain comatose after 40h should be kept at a normothermic level (36.5 - 37.7°C) until 72h after randomization and active warming should be avoided.

Participants who remain unconscious four days after randomization will be assessed according to a conservative protocol based on the European Resuscitation Council's recommendations for withdrawal of life sustaining therapies.

Follow up will be performed at:

1 month (face-to-face or telephone), Assessment according to the modified Rankin scale (mRS)

6 moths (face-to-face), Assessment according to the mRS-scale. Assessment of health-related quality of life using EQ5D-5L.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Out-of-hospital Cardiac Arrest

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
The clinical team responsible for the participant (physicians, nurses and others) and involved with direct patient care will not be blinded to allocation group due to the inherent difficulty in blinding the intervention and as temperature is a vital sign required for clinical care. Measures will be taken to ensure that the information about allocation will not disseminate beyond the immediate group of caregivers responsible for patient care. A blinded physician will evaluate the patient at 96 hours after randomisation and make a statement on neurological prognosis.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normothermia

Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.

Group Type ACTIVE_COMPARATOR

Standard care with early treatment of fever

Intervention Type PROCEDURE

Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C

Hypothermia

Targeted temperature management to 33°C for up to 28h.

Group Type EXPERIMENTAL

Targeted temperature management to 33°C

Intervention Type PROCEDURE

Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Targeted temperature management to 33°C

Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.

Intervention Type PROCEDURE

Standard care with early treatment of fever

Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Out-of-hospital cardiac arrest
* Presumed cardiac cause of cardiac arrest
* Unconscious with a FOUR-score \<M4 (not obeying verbal commands)
* Stable return of spontaneous circulation (20 min)
* Eligible for intensive care treatment without restrictions
* Inclusion within 180 minutes of ROSC

Exclusion Criteria

* Unwitnessed cardiac arrest with an initial rhythm of asystole
* Temperature on admission \<30°C.
* On ECMO prior to ROSC
* Obvious or suspected pregnancy
* Intracranial bleeding
* On ECMO prior to ROSC
* Severe chronic obstructive pulmonary disorder (COPD) with long-term home oxygen therapy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lund University

OTHER

Sponsor Role collaborator

Region Skåne - Skånevård SUND

UNKNOWN

Sponsor Role collaborator

Copenhagen Trial Unit, Center for Clinical Intervention Research

OTHER

Sponsor Role collaborator

Clinical Trials Sweden, Forum South

UNKNOWN

Sponsor Role collaborator

Integrated Biobank of Luxembourg

OTHER

Sponsor Role collaborator

Helsingborgs Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Niklas Nielsen

MD, PhD, Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Niklas Nielsen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Helsingborgs lasarett, Region Skåne, Sweden

Hans Friberg, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Lund University Hospital, Lund, Sweden

Tobias Cronberg, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Lund University Hospital, Lund, Sweden

Jan Hovdenes, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Oslo University Hospital, Oslo, Norway

Matt P Wise, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital of Wales, Cardiff, UK

Clifton W Callaway, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh, Pittsburgh, USA

Christian Storm, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Charité-University Medicine (Berlin, Germany)

Alain Cariou, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Université Paris Descartes, France

David Erlinge, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Lund University Hospital, Lund, Sweden

Christian Rylander, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Sahlgrenska University Hospital

Josef Dankiewicz, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Skåne University Hospital Lund

Mauro Oddo, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Université de Lausanne, Lausanne, Switzerland

Manoj Saxena, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

The George Institute for Global Health (Sydney, Australia)

Per Nordberg, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Södersjukhuset, Stockholm

Fabio Taccone, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hopital Erasme, Brussles, Belgium

Paolo Pelosi, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

San Martino University Hospital, Genoa

Michael Ioannidis, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Innsbruck University Hospital

Jan Belholavek, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Prague University Hospital

Paul Young, MD

Role: PRINCIPAL_INVESTIGATOR

Wellington Regional Hospital

Hans Kirkegaard, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital

Alistair Nichol, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Anaesthesia and Intensive Care Medicine, St Vincent's University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic Hospital-St. Mary's Campus

Rochester, New York, United States

Site Status

UPMC-Presbyterian

Pittsburgh, Pennsylvania, United States

Site Status

John Hunter Hospital

Newcastle, New South Wales, Australia

Site Status

Concord Repatriation General Hospital

Sydney, New South Wales, Australia

Site Status

Liverpool Hospital

Sydney, New South Wales, Australia

Site Status

St Vincent's Hospital

Sydney, New South Wales, Australia

Site Status

Princess Alexandra Hospital

Brisbane, Queensland, Australia

Site Status

Northern Hospital

Epping, Victoria, Australia

Site Status

The Alfred

Melbourne, Victoria, Australia

Site Status

Austin Hospital

Melbourne, , Australia

Site Status

Nepean Hospital

Sydney, , Australia

Site Status

Royal North Shore Hospital

Sydney, , Australia

Site Status

Innsbruck University Hospital

Innsbruck, , Austria

Site Status

Erasme Hospital

Brussels, , Belgium

Site Status

Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status

Hradec Kralove Hospital

Hradec Králové, , Czechia

Site Status

Liberec Hospital

Liberec, , Czechia

Site Status

General University Hospital

Prague, , Czechia

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Chu Dupuytren

Limoges, , France

Site Status

CHU Nantes

Nantes, , France

Site Status

Cochin University Hospital

Paris, , France

Site Status

Lariboisière Hospital

Paris, , France

Site Status

Versailles Hospital

Versailles, , France

Site Status

Charité, Campus Virchow

Berlin, , Germany

Site Status

San Martino Hospital

Genova, , Italy

Site Status

Modena NOCSAE Hospital

Modena, , Italy

Site Status

Christchurch Hospital

Christchurch, , New Zealand

Site Status

Wellington Hospital

Wellington, , New Zealand

Site Status

Sorlandet Hospital

Arendal, , Norway

Site Status

Haukeland Hospital

Bergen, , Norway

Site Status

Oslo University Hospital

Oslo, , Norway

Site Status

St. Olav's University Hospital

Trondheim, , Norway

Site Status

Hallands Hospital

Halmstad, Halland County, Sweden

Site Status

Skane University Hospital - Lund

Lund, Skåne County, Sweden

Site Status

Skane University Hospital - Malmö

Malmo, Skåne County, Sweden

Site Status

Sahlgrenska University Hospital

Gothenburg, , Sweden

Site Status

Helsingborgs Hospital

Helsingborg, , Sweden

Site Status

Centralsjukhuset i Karlstad

Karlstad, , Sweden

Site Status

Linköping University Hospital

Linköping, , Sweden

Site Status

Örebro University Hospital

Örebro, , Sweden

Site Status

Skaraborgs sjukhus

Skövde, , Sweden

Site Status

Capio St:Göran

Stockholm, , Sweden

Site Status

Södersjukhuset

Stockholm, , Sweden

Site Status

Norra Älvsborgs Länssjukhus (NÄL)

Trollhättan, , Sweden

Site Status

Akademiska Sjukhuset

Uppsala, , Sweden

Site Status

University Hospital Bern, Inselspital

Bern, , Switzerland

Site Status

University Hospital of Lausanne

Lausanne, , Switzerland

Site Status

Cardiocentro Ticino

Lugano, , Switzerland

Site Status

Kantonsspital St.Gallen

Sankt Gallen, , Switzerland

Site Status

Zurich University Hospital

Zurich, , Switzerland

Site Status

Basildon and Thurrock Hospitals NHS Foundation Trust - Essex CTC

Basildon, , United Kingdom

Site Status

Royal Victoria Hospital

Belfast, , United Kingdom

Site Status

Birmingham University Hospital

Birmingham, , United Kingdom

Site Status

Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

Bournemouth, , United Kingdom

Site Status

Bristol Royal Infirmary

Bristol, , United Kingdom

Site Status

University Hospital of Wales

Cardiff, , United Kingdom

Site Status

Manchester Royal Infirmary

Manchester, , United Kingdom

Site Status

Queen Alexandra Hospital

Portsmouth, , United Kingdom

Site Status

Royal Berkshire Hospital

Reading, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Czechia Denmark France Germany Italy New Zealand Norway Sweden Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Aneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Kober L, Langorgen J, Lilja G, Moller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H; TTM Trial Investigators. Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med. 2013 Dec 5;369(23):2197-206. doi: 10.1056/NEJMoa1310519. Epub 2013 Nov 17.

Reference Type BACKGROUND
PMID: 24237006 (View on PubMed)

Admiraal MM, Backman S, Annborn M, Borgquist O, Dankiewicz J, During J, Legriel S, Lilja G, Lindehammer H, Nielsen N, Rossetti AO, Unden J, Cronberg T, Westhall E; TTM2-trial investigators. Electrographic and Clinical Determinants of Good Outcome After Postanoxic Status Epilepticus. Neurology. 2025 Mar 11;104(5):e210304. doi: 10.1212/WNL.0000000000210304. Epub 2025 Feb 11.

Reference Type DERIVED
PMID: 39933130 (View on PubMed)

Taccone FS, Cariou A, Zorzi S, Friberg H, Jakobsen JC, Nordberg P, Robba C, Belohlavek J, Hovdenes J, Haenggi M, Aneman A, Grejs A, Keeble TR, Annoni F, Young PJ, Wise MP, Cronberg T, Lilja G, Nielsen N, Dankiewicz J. Hypothermia versus normothermia in patients with cardiac arrest and shockable rhythm: a secondary analysis of the TTM-2 study. Crit Care. 2024 Oct 15;28(1):335. doi: 10.1186/s13054-024-05119-3.

Reference Type DERIVED
PMID: 39407230 (View on PubMed)

Heimburg K, Blennow Nordstrom E, Dankiewicz J, Friberg H, Grejs AM, Hanggi M, Keeble TR, Kirkegaard H, Nielsen N, Rylander C, Tornberg AB, Ullen S, Wise MP, Cronberg T, Lilja G. Low physical activity level in out-of-hospital cardiac arrest survivors with obesity, mobility problems and cognitive impairment: Results from the TTM2 trial. Resuscitation. 2024 Nov;204:110407. doi: 10.1016/j.resuscitation.2024.110407. Epub 2024 Oct 4.

Reference Type DERIVED
PMID: 39368797 (View on PubMed)

Battaglini D, Schiavetti I, Ball L, Jakobsen JC, Lilja G, Friberg H, Wendel-Garcia PD, Young PJ, Eastwood G, Chew MS, Unden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Hammond N, Saxena M, Martin A, Solar M, Taccone FS, Dankiewicz J, Nielsen N, Morten Grejs A, Wise MP, Hangghi M, Smid O, Patroniti N, Robba C; TTM2 trial investigators. Association between early airway intervention in the pre-hospital setting and outcomes in out of hospital cardiac arrest patients: A post-hoc analysis of the Target Temperature Management-2 (TTM2) trial. Resuscitation. 2024 Oct;203:110390. doi: 10.1016/j.resuscitation.2024.110390. Epub 2024 Sep 5.

Reference Type DERIVED
PMID: 39244144 (View on PubMed)

Lang M, Kenda M, Scheel M, Martola J, Wheeler M, Owen S, Johnsson M, Annborn M, Dankiewicz J, Deye N, During J, Friberg H, Halliday T, Jakobsen JC, Lascarrou JB, Levin H, Lilja G, Lybeck A, McGuigan P, Rylander C, Sem V, Thomas M, Ullen S, Unden J, Wise MP, Cronberg T, Wasselius J, Nielsen N, Leithner C, Moseby-Knappe M. Standardised and automated assessment of head computed tomography reliably predicts poor functional outcome after cardiac arrest: a prospective multicentre study. Intensive Care Med. 2024 Jul;50(7):1096-1107. doi: 10.1007/s00134-024-07497-2. Epub 2024 Jun 20.

Reference Type DERIVED
PMID: 38900283 (View on PubMed)

Holgersson J, Meyer MAS, Dankiewicz J, Lilja G, Ullen S, Hassager C, Cronberg T, Wise MP, Belohlavek J, Hovdenes J, Pelosi P, Erlinge D, Schrag C, Smid O, Brunetti I, Rylander C, Young PJ, Saxena M, Aneman A, Cariou A, Callaway C, Eastwood GM, Haenggi M, Joannidis M, Keeble TR, Kirkegaard H, Leithner C, Levin H, Nichol AD, Morgan MPG, Nordberg P, Oddo M, Storm C, Taccone FS, Thomas M, Bro-Jeppesen J, Horn J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher MJ, Friberg H, Nielsen N, Jakobsen JC. Hypothermic versus Normothermic Temperature Control after Cardiac Arrest. NEJM Evid. 2022 Nov;1(11):EVIDoa2200137. doi: 10.1056/EVIDoa2200137. Epub 2022 Jun 15.

Reference Type DERIVED
PMID: 38319850 (View on PubMed)

Lilja G, Ullen S, Dankiewicz J, Friberg H, Levin H, Nordstrom EB, Heimburg K, Jakobsen JC, Ahlqvist M, Bass F, Belohlavek J, Olsen RB, Cariou A, Eastwood G, Fanebust HR, Grejs AM, Grimmer L, Hammond NE, Hovdenes J, Hrecko J, Iten M, Johansen H, Keeble TR, Kirkegaard H, Lascarrou JB, Leithner C, Lesona ME, Levis A, Mion M, Moseby-Knappe M, Navarra L, Nordberg P, Pelosi P, Quayle R, Rylander C, Sandberg H, Saxena M, Schrag C, Siranec M, Tiziano C, Vignon P, Wendel-Garcia PD, Wise MP, Wright K, Nielsen N, Cronberg T. Effects of Hypothermia vs Normothermia on Societal Participation and Cognitive Function at 6 Months in Survivors After Out-of-Hospital Cardiac Arrest: A Predefined Analysis of the TTM2 Randomized Clinical Trial. JAMA Neurol. 2023 Oct 1;80(10):1070-1079. doi: 10.1001/jamaneurol.2023.2536.

Reference Type DERIVED
PMID: 37548968 (View on PubMed)

Robba C, Badenes R, Battaglini D, Ball L, Sanfilippo F, Brunetti I, Jakobsen JC, Lilja G, Friberg H, Wendel-Garcia PD, Young PJ, Eastwood G, Chew MS, Unden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Hammond N, Saxena M, Martin A, Solar M, Taccone FS, Dankiewicz J, Nielsen N, Grejs AM, Ebner F, Pelosi P; TTM2 Trial collaborators. Oxygen targets and 6-month outcome after out of hospital cardiac arrest: a pre-planned sub-analysis of the targeted hypothermia versus targeted normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial. Crit Care. 2022 Oct 21;26(1):323. doi: 10.1186/s13054-022-04186-8.

Reference Type DERIVED
PMID: 36271410 (View on PubMed)

Lang M, Leithner C, Scheel M, Kenda M, Cronberg T, During J, Rylander C, Annborn M, Dankiewicz J, Deye N, Halliday T, Lascarrou JB, Matthew T, McGuigan P, Morgan M, Thomas M, Ullen S, Unden J, Nielsen N, Moseby-Knappe M. Prognostic accuracy of head computed tomography for prediction of functional outcome after out-of-hospital cardiac arrest: Rationale and design of the prospective TTM2-CT-substudy. Resusc Plus. 2022 Oct 12;12:100316. doi: 10.1016/j.resplu.2022.100316. eCollection 2022 Dec.

Reference Type DERIVED
PMID: 36267356 (View on PubMed)

During J, Annborn M, Cariou A, Chew MS, Dankiewicz J, Friberg H, Haenggi M, Haxhija Z, Jakobsen JC, Langeland H, Taccone FS, Thomas M, Ullen S, Wise MP, Nielsen N. Influence of temperature management at 33 degrees C versus normothermia on survival in patients with vasopressor support after out-of-hospital cardiac arrest: a post hoc analysis of the TTM-2 trial. Crit Care. 2022 Jul 31;26(1):231. doi: 10.1186/s13054-022-04107-9.

Reference Type DERIVED
PMID: 35909163 (View on PubMed)

Robba C, Badenes R, Battaglini D, Ball L, Brunetti I, Jakobsen JC, Lilja G, Friberg H, Wendel-Garcia PD, Young PJ, Eastwood G, Chew MS, Unden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Hammond N, Saxena M, Annborn M, Solar M, Taccone FS, Dankiewicz J, Nielsen N, Pelosi P; TTM2 Trial Collaborators. Ventilatory settings in the initial 72 h and their association with outcome in out-of-hospital cardiac arrest patients: a preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (TTM2) trial. Intensive Care Med. 2022 Aug;48(8):1024-1038. doi: 10.1007/s00134-022-06756-4. Epub 2022 Jul 2.

Reference Type DERIVED
PMID: 35780195 (View on PubMed)

Robba C, Nielsen N, Dankiewicz J, Badenes R, Battaglini D, Ball L, Brunetti I, Pedro David WG, Young P, Eastwood G, Chew MS, Jakobsen J, Unden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Lilja G, Hammond NE, Saxena M, Martin A, Solar M, Taccone FS, Friberg HA, Pelosi P. Ventilation management and outcomes in out-of-hospital cardiac arrest: a protocol for a preplanned secondary analysis of the TTM2 trial. BMJ Open. 2022 Mar 3;12(3):e058001. doi: 10.1136/bmjopen-2021-058001.

Reference Type DERIVED
PMID: 35241476 (View on PubMed)

Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullen S, Rylander C, Wise MP, Oddo M, Cariou A, Belohlavek J, Hovdenes J, Saxena M, Kirkegaard H, Young PJ, Pelosi P, Storm C, Taccone FS, Joannidis M, Callaway C, Eastwood GM, Morgan MPG, Nordberg P, Erlinge D, Nichol AD, Chew MS, Hollenberg J, Thomas M, Bewley J, Sweet K, Grejs AM, Christensen S, Haenggi M, Levis A, Lundin A, During J, Schmidbauer S, Keeble TR, Karamasis GV, Schrag C, Faessler E, Smid O, Otahal M, Maggiorini M, Wendel Garcia PD, Jaubert P, Cole JM, Solar M, Borgquist O, Leithner C, Abed-Maillard S, Navarra L, Annborn M, Unden J, Brunetti I, Awad A, McGuigan P, Bjorkholt Olsen R, Cassina T, Vignon P, Langeland H, Lange T, Friberg H, Nielsen N; TTM2 Trial Investigators. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. N Engl J Med. 2021 Jun 17;384(24):2283-2294. doi: 10.1056/NEJMoa2100591.

Reference Type DERIVED
PMID: 34133859 (View on PubMed)

Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Belohlavek J, Callaway C, Cariou A, Eastwood G, Erlinge D, Hovdenes J, Joannidis M, Kirkegaard H, Kuiper M, Levin H, Morgan MPG, Nichol AD, Nordberg P, Oddo M, Pelosi P, Rylander C, Saxena M, Storm C, Taccone F, Ullen S, Wise MP, Young P, Friberg H, Nielsen N. Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2): A randomized clinical trial-Rationale and design. Am Heart J. 2019 Nov;217:23-31. doi: 10.1016/j.ahj.2019.06.012. Epub 2019 Jun 26.

Reference Type DERIVED
PMID: 31473324 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://ttm2trial.org

Trial official webpage

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TTM-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of TTM in Adults With ECPR.
NCT06608095 ACTIVE_NOT_RECRUITING NA